BRPI0917562A8 - Composição farmacêutica estabilizada contra oxidação - Google Patents

Composição farmacêutica estabilizada contra oxidação

Info

Publication number
BRPI0917562A8
BRPI0917562A8 BRPI0917562A BRPI0917562A BRPI0917562A8 BR PI0917562 A8 BRPI0917562 A8 BR PI0917562A8 BR PI0917562 A BRPI0917562 A BR PI0917562A BR PI0917562 A BRPI0917562 A BR PI0917562A BR PI0917562 A8 BRPI0917562 A8 BR PI0917562A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
light
clevidipine
against oxidation
h324ns
Prior art date
Application number
BRPI0917562A
Other languages
English (en)
Inventor
Motheram Rajeshwar
Krishna Gopal
Ding Min
Original Assignee
The Medicines Co
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co, Chiesi Farm Spa filed Critical The Medicines Co
Publication of BRPI0917562A2 publication Critical patent/BRPI0917562A2/pt
Publication of BRPI0917562A8 publication Critical patent/BRPI0917562A8/pt
Publication of BRPI0917562B1 publication Critical patent/BRPI0917562B1/pt
Publication of BRPI0917562B8 publication Critical patent/BRPI0917562B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA ESTABILIZADA CONTRA OXIDAÇÃO. Composições farmacêuticas, e um método de estabilizar as composições farmacêuticas tendo clevidipina, ou qualquer sal farmaceuticamente aceitável da mesma, como o ingrediente ativo é descrito. O método inclui diminuir ou inibir a via de oxidação da clevidipina. Isto pode ser realizado reduzindo a quantidade que a composição farmacêutica é exposta ao oxigênio e/ou á luz durante os processos de fabricação e armazenamento. De acordo com este método, oxigênio deve ser removido ou substituído, ou luz deve ser suficientemente bloqueada de modo que a energia da luz não pode alcançar o ingrediente ativo da composição, ou é reduzida para um nível que a reação de oxidação induzida por luz que converte clevidipina para H324nS é minimizada, de modo que p nível detectável total de H324nS em uma amostra de composição dada não execede cerca 0 2% em uma base de peso por peso.
BRPI0917562A 2008-08-01 2009-07-30 composição farmacêutica estabilizada contra oxidação BRPI0917562B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8559408P 2008-08-01 2008-08-01
US61/085,594 2008-08-01
US9381008P 2008-09-03 2008-09-03
US61/093,810 2008-09-03
PCT/US2009/004399 WO2010014234A1 (en) 2008-08-01 2009-07-30 Pharmaceutical compositions and methods for stabilizing the same

Publications (4)

Publication Number Publication Date
BRPI0917562A2 BRPI0917562A2 (pt) 2017-06-20
BRPI0917562A8 true BRPI0917562A8 (pt) 2017-12-12
BRPI0917562B1 BRPI0917562B1 (pt) 2021-04-06
BRPI0917562B8 BRPI0917562B8 (pt) 2021-05-25

Family

ID=41610652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917562A BRPI0917562B8 (pt) 2008-08-01 2009-07-30 composição farmacêutica estabilizada contra oxidação

Country Status (21)

Country Link
US (4) US20100105743A1 (pt)
EP (1) EP2320739B1 (pt)
JP (4) JP2011529879A (pt)
KR (4) KR20160095206A (pt)
CN (2) CN106377501A (pt)
AU (1) AU2009277100B2 (pt)
BR (1) BRPI0917562B8 (pt)
CA (1) CA2732692C (pt)
CY (1) CY1122526T1 (pt)
DK (1) DK2320739T3 (pt)
EA (1) EA201170287A1 (pt)
ES (1) ES2770178T3 (pt)
HR (1) HRP20200136T1 (pt)
HU (1) HUE047692T2 (pt)
LT (1) LT2320739T (pt)
MX (1) MX2011001241A (pt)
NZ (1) NZ591204A (pt)
PL (1) PL2320739T3 (pt)
PT (1) PT2320739T (pt)
SI (1) SI2320739T1 (pt)
WO (1) WO2010014234A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076334A1 (en) * 2009-09-30 2011-03-31 Robert Cook Methods and compositions for treatment of raynaud's phenomenon
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
JP2014509654A (ja) * 2011-04-01 2014-04-21 ザ メディシンズ カンパニー 脳卒中損傷の低減に使用するための短時間作用型ジヒドロピリジン（クレビジピン）
CN103134891A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 一种丁酸氯维地平含量和有关物质的测定方法
BR112015009291B1 (pt) 2012-10-26 2021-03-16 Chiesi Farmaceutici S.P.A uso de clevidipina para controle da pressão arterial e redução da dispneia na insuficiência cardíaca
CN103520104B (zh) * 2013-10-25 2015-08-26 北京蓝丹医药科技有限公司 丁酸氯维地平脂肪乳注射液及其制备方法
CN109776405A (zh) * 2019-03-07 2019-05-21 重庆安格龙翔医药科技有限公司 一种丁酸氯维地平杂质的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756779A (fr) * 1969-09-30 1971-03-01 Warner Lambert Pharmaceutical Solutions stables de cardenolides sensibles a l'oxydation
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
JP2000247883A (ja) * 1999-02-23 2000-09-12 Fujisawa Pharmaceut Co Ltd ジヒドロピリジン系化合物を含有する内服用液剤
US20030102246A1 (en) * 1999-03-20 2003-06-05 Lts Lohmann Therapie-Systeme Ag Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
JP2003104888A (ja) * 2001-09-28 2003-04-09 Taiyo Yakuhin Kogyo Kk ジヒドロピリジン誘導体の錠剤
DE10224612A1 (de) * 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
JP4667867B2 (ja) * 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
EP1813274B1 (en) * 2004-10-06 2009-12-16 Eisai R&D Management Co., Ltd. Medicinal composition, process for producing the same, and method of stabilizing dihydropyridine compound in medicinal composition
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070196465A1 (en) * 2005-07-28 2007-08-23 George Bobotas Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
US7612102B2 (en) * 2006-04-18 2009-11-03 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions

Also Published As

Publication number Publication date
AU2009277100B2 (en) 2015-05-28
KR20180059956A (ko) 2018-06-05
SI2320739T1 (sl) 2020-03-31
CA2732692C (en) 2019-12-24
LT2320739T (lt) 2020-01-27
US20120322836A1 (en) 2012-12-20
BRPI0917562A2 (pt) 2017-06-20
EP2320739B1 (en) 2019-11-27
HUE047692T2 (hu) 2020-05-28
WO2010014234A1 (en) 2010-02-04
BRPI0917562B8 (pt) 2021-05-25
MX2011001241A (es) 2011-08-03
CY1122526T1 (el) 2021-01-27
KR20160095206A (ko) 2016-08-10
US20190117660A1 (en) 2019-04-25
ES2770178T3 (es) 2020-06-30
US20230302002A1 (en) 2023-09-28
JP2011529879A (ja) 2011-12-15
NZ591204A (en) 2013-02-22
JP2015098472A (ja) 2015-05-28
EP2320739A4 (en) 2011-08-24
CN102186351A (zh) 2011-09-14
DK2320739T3 (da) 2020-02-24
CA2732692A1 (en) 2010-02-04
JP2016216501A (ja) 2016-12-22
BRPI0917562B1 (pt) 2021-04-06
HRP20200136T1 (hr) 2020-08-21
PL2320739T3 (pl) 2020-06-01
EA201170287A1 (ru) 2011-10-31
EP2320739A1 (en) 2011-05-18
KR20170051542A (ko) 2017-05-11
PT2320739T (pt) 2020-02-18
JP2017081980A (ja) 2017-05-18
KR20110059843A (ko) 2011-06-07
KR101946977B1 (ko) 2019-05-21
CN106377501A (zh) 2017-02-08
AU2009277100A1 (en) 2010-02-04
JP6537538B2 (ja) 2019-07-03
US20100105743A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0917562A8 (pt) Composição farmacêutica estabilizada contra oxidação
Bos et al. Hydrogen sulfide: physiological properties and therapeutic potential in ischaemia
Bordia et al. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
NO20090590L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
BR0014869A (pt) Composição e método para estabilização da mesma
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
DK2051976T3 (da) 4-[5-Methoxy-6-(2-methyl-6[1,2,4)triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidin-1-carboxylsyre-isopropylester som modulator af metabolisme og behandling af lidelser beslægtet dermed
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
DK1411900T4 (da) Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BR112014025132A2 (pt) formulações de insulina
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0720500A8 (pt) Preparação líquida transdérmica
JP2014518274A5 (pt)
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
WO1997039729A1 (en) Nsaid/fluoride periodontal compositions
AR052888A1 (es) Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
Hucks et al. Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL
BR112013018738A2 (pt) novos derivados de tetrahidroquinolina
UY32644A (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CHIESI FARMACEUTICI S.P.A. (IT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF